Eli Lilly & Co.'s Verzenio (abemaciclib), now approved for breast cancer, will compete for market share in a crowded category that already includes two rival cyclin dependent kinase 4/6 (CDK4/6) inhibitors – Pfizer Inc.'s well-entrenched Ibrance (palbociclib) and Novartis AG's newcomer Kisqali (ribociclib) – but it isn't setting out to do so based on price.
And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer
Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.
More from New Products
More from Scrip
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.